PLYX
HEALTHCAREPolaryx Therapeutics Inc
$3.80-0.74 (-16.30%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PLYX Today?
No stock-specific AI insight has been generated for PLYX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.20$48.91
$3.80
Fundamentals
Market Cap$180M
P/E Ratio—
EPS$-0.19
Dividend Yield—
Dividend / Share—
ROE-1.9%
Profit Margin—
Debt / Equity—
Trading
Volume337K
Avg Volume (10D)—
Shares Outstanding47.3M
PLYX News
14 articles- Polaryx Therapeutics to Participate in National Tay-Sachs & Allied Diseases Association Annual Family ConferenceYahoo Finance·Apr 23, 2026
- Polaryx Therapeutics Receives U.S. FDA Fast Track Designations for All Four Indications to be Evaluated in the SOTERIA Basket TrialYahoo Finance·Apr 21, 2026
- Polaryx Therapeutics Recognized with Pinnacle Award for Excellence in Pediatric CareYahoo Finance·Apr 15, 2026
- Polaryx Therapeutics To Participate In The 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 1, 2026
- Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)Yahoo Finance·Mar 17, 2026
- Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy EventsYahoo Finance·Mar 12, 2026
- Polaryx Therapeutics Marks Rare Disease Day, Reaffirming Commitment to Patients with Rare Pediatric Lysosomal Storage DisordersYahoo Finance·Feb 27, 2026
- Polaryx Therapeutics Selects Contract Research Organization for SOTERIA Phase 2 Basket TrialYahoo Finance·Feb 17, 2026
- Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™Yahoo Finance·Feb 10, 2026
- Polaryx Therapeutics Welcomes New Members of the Board of DirectorsYahoo Finance·Feb 5, 2026
- Polaryx to present late-breaker data related to Soteria ahead of trialYahoo Finance·Feb 4, 2026
- Polaryx to Present Late-Breaker Data Related to SOTERIA at the 22nd Annual WORLDSymposium™ as Company Prepares for SOTERIA Trial LaunchYahoo Finance·Feb 3, 2026
- Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”Yahoo Finance·Feb 2, 2026
- Polaryx Therapeutics Announces Approval to List Common Stock on NasdaqYahoo Finance·Jan 30, 2026
All 14 articles loaded
Price Data
Open$4.70
Previous Close$4.54
Day High$4.75
Day Low$3.10
52 Week High$48.91
52 Week Low$2.20
52-Week Range
$2.20$48.91
$3.80
Fundamentals
Market Cap$180M
P/E Ratio—
EPS$-0.19
Dividend Yield—
Dividend / Share—
ROE-1.9%
Profit Margin—
Debt / Equity—
Trading
Volume337K
Avg Volume (10D)—
Shares Outstanding47.3M
About Polaryx Therapeutics Inc
Polaryx Therapeutics, Inc., clinical-stage biotechnology company, develops small molecule and gene therapy treatments for lysosomal storage disorders. The company is headquartered in Paramus, New Jersey.
Listed February 2, 2026
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—